Gustave Roussy Cancer Center, Villejuif, France.
Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Nat Cancer. 2020 Oct;1(10):946-964. doi: 10.1038/s43018-020-00122-3. Epub 2020 Oct 2.
Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.
2019 年冠状病毒病（COVID-19）及其病原体 SARS-CoV-2 给肿瘤患者的管理带来了巨大挑战。COVID-19 在衰老和免疫抑制个体中表现为一种特别严重的呼吸道和全身感染，包括癌症患者。此外，严重的 COVID-19 与炎症爆发和淋巴细胞减少有关，这可能会加重癌症的预后。在这里，我们讨论了为什么癌症患者患严重 COVID-19 的风险更高，描述了对这种疾病产生保护或不良反应的免疫反应，并指出哪些抗肿瘤疗法可能会增加 COVID-19 的脆弱性，或者对癌症和 COVID-19 具有双重治疗作用。
